Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANRG -- Anergen -- new CEO big chance ? -- Ignore unavailable to you. Want to Upgrade?

To: Douglas who wrote (91)	4/28/1998 4:38:00 PM
From: Douglas	Read Replies (1) \| Respond to of 123

Growing Importance of Genetic Predisposition in Autoimmune Disease Highlighted At Major Immunology Symposium REDWOOD CITY, Calif., April 28 /PRNewswire/ -- New therapies may prove successful in treating autoimmune diseases caused by the interaction between disease-linked MHC (major histocompatibility complex) molecules and certain immune system cells (T cells), according to presentations by scientists from Johns Hopkins University, Stanford University, and Anergen, Inc. (Nasdaq: ANRG - news). The presentations were made at a research symposium at the annual meeting of the American Association of Immunologists in San Francisco. ''These scientific presentations underscore the need for new therapeutics that can directly and precisely intervene in the interaction between particular MHCs and T cells, an event that sets in motion a cascade of damaging immune responses in patients,'' said Barry Sherman, M.D., President and CEO of Anergen. ''Such approaches in the form of Anergen's AnervaX(TM) and AnergiX(TM) technologies are showing great promise in Phase I (safety) and Phase II (safety and efficacy) trials in multiple sclerosis and rheumatoid arthritis, as well as in preclinical evaluations for diabetes, and other prevalent autoimmune conditions.'' ''The link of MHC molecules to the onset of these diseases has been supported by genetic predisposition studies worldwide,'' said Maureen Howard, Ph.D., Vice President, Research and symposium speaker. ''MHC molecules are found on the surface of all cells in the body. Each provides a highly distinctive biochemical signature that can activate the response of T cells that trigger immune responses against bacterial and viral invaders. Genetic subtypes of certain MHCs are linked to increased risk for major autoimmune diseases, such as rheumatoid arthritis.'' It is possible to specifically block the interaction of these disease-linked MHC molecules with autoreactive T cells using either a therapeutic peptide vaccine (AnervaX) that stimulates the production of a neutralizing immune response that prevents the autoimmune disease cascade; or a complex of an MHC-derived protein and a disease specific autoantigenic (AnergiX), that serves to downregulate autoreactive T cell responses. ''Symposium panelists expressed strong support for the development of MHC-targeted therapeutics both as a highly efficient means of leveraging the growing body of genetic information related to common autoimmune diseases, and as a pathway for new drugs that promise greater safety and specificity,'' said Carol Nacy, Ph.D., Chief Scientific Officer at Anergen and chairperson of the symposium. Anergen, Inc. is a biotechnology company focused on advancing the treatment of autoimmune diseases. The Company is developing proprietary biopharmaceutical compounds designed to selectively interrupt antigen presentation or inactivate T cells in the immune system that mediate the disease process. NOTE: Certain statements in this press release about the Company's utilization of resources, product development activities, clinical trials, and product pipelines, other than statements of historical fact, are forward looking statements, and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties. The Company's actual results could differ materially from the results discussed in these forward looking statements. Factors that could cause or contribute to such differences include dependence upon collaborative partners for the advancement of the company's research and development activities, uncertainties related to preclinical and clinical trials , government regulation; no assurance of obtaining product approvals, and future requirements for additional capital. These items are discussed in the Company's Form 10-K filed for fiscal years 1997 and the reports filed on Form 10-Q.